Clinical Trial Update: The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating Yttrium-90 Zevalin in patients with Diffuse Large B-cell Lymphoma after 6 cycles of CHOP has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Mahidol University | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED